secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2024-08-16T23:59:59+00:00
Accession:  0001213900-24-070285
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharma completes SPAC merger, forms Citius Oncology; holds ~90% of new public company
--------------------------------------------------------------------------------

- Merger closed Aug 12, 2024; Citius Oncology expected to trade on Nasdaq as CTOR on Aug 13.
- Citius Pharma owns approximately 90% of Citius Oncology after the merger.
- LYMPHIR (denileukin diftitox) approved by FDA for relapsed/refractory cutaneous T-cell lymphoma.
- Citius Pharma made $3.8M capital contribution to Citius Oncology via no-interest promissory note.
- Amended shared services and registration rights agreements executed; shares subject to 6-month lock-up.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390024070285/0001213900-24-070285-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390024070285/ea0211482-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-070285

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer